Baraclude gives off its throne in 7 years, continued by Viread
No throne can last forever.
‘Baraclude,’ which has kept its top position for 7 consecutive years in the hepatitis B therapy market since 2011, has been weakened due to aggressive attacks of generics since October last year.
According to the analysis result of the 2016 1st half’s prescription ...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
